stock · yahoo

ELV

ELV

$426.55
▼ 1.71 (-0.4%)
Last close · Oct 19

Below: live stock price for ELV (ELV), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

ELV (ELV) is a Healthcare company based in United States. Operating in Healthcare Plans, it employs about 96,129 people. Over the past year ELV traded between 274.84 and 436.24 USD. It currently yields 1.60% in dividends.

Day
-0.40%
-1.71
Week
+1.06%
+4.46
Month
+3.80%
+15.60
Year
—
Prev close
$428.26
Volume (24h)
—
Market cap
—
Currency
USD

Score

50/ 100 · Mixed

Coverage: 7/7
  • Value68
  • Quality35
  • Momentum47
  • Growth24
  • Risk79
  • Dividend55
  • Liquidity44

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

UptrendFit 41%Pace +0.13% per bar
+5 bars+20 bars+60 bars+120 bars
+5 bars
428.6687
+0.50%
Bull482.6636
Bear380.7142
+20 bars
431.6023
+1.18%
Bull547.1789
Bear340.4382
+60 bars
432.7426
+1.45%
Bull652.6942
Bear286.9126
+120 bars
432.7845
+1.46%
Bull773.8925
Bear242.0264

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0265 USD.

Interpretation

Composite signals look mixed. Strength: risk profile with weakness: growth. Price sits near the upper third of the recent range, trend is sloping upward.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

  • Value
    68/100

    Value looks solid — driven by P/E (18.96).

    P/E:18.96P/B:2.08PEG:1.4
  • Quality
    35/100

    Quality looks weak — driven by Gross margin (25.99%).

    ROE:11.13%ROA:3.83%Profit margin:2.47%Gross margin:25.99%
  • Momentum
    47/100

    Momentum looks mixed — driven by 52w change (20.95%).

    52w change:20.95%
  • Growth
    24/100

    Growth looks fragile — driven by Earnings growth (-13.10%).

    Revenue growth:1.40%Earnings growth:-13.10%
  • Risk
    79/100

    Risk looks strong — driven by Debt / equity (68.95).

    Beta:0.71Debt / equity:68.95Short interest:2.51%
  • Dividend
    55/100

    Dividend looks mixed — driven by Payout ratio (30.37%).

    Dividend yield:1.60%Payout ratio:30.37%
  • Liquidity
    44/100

    Liquidity looks weak — driven by Current ratio (1.52).

    Current ratio:1.52Quick ratio:1.37

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 251 days.

Position in range94%
274.84 low436.24 high

Where the price sits between the window low and high.

Volatility (annualised)
35.5%

Spread of returns. Higher means larger swings in both directions.

Max drawdown
-26.5%

Worst peak-to-trough fall inside the window.

Below period high
-2.2%

Current price against the highest point in the window.

Best day
+7.62%
Worst day
-14.33%
Up days
52%

Share of days that closed above the one before.

Current streak
2 down
Typical day swing
2.8%

Average high-to-low spread within a single day.

Volume vs average
-5%

Last 10 days against the whole window.

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above
455.2254 USD+6.72%
Fib +27.2% extension
Next level below
418.3853 USD-1.92%
Fib 23.6% retracement

Levels derived from: 435.5 high → 362.98 low · 60 bars

  • Resistance
    Fib +161.8% extension
    not reached
    552.8373 USD
    +29.61% from current
  • Resistance
    Fib +100% extension
    not reached
    508.02 USD
    +19.10% from current
  • Resistance
    Fib +61.8% extension
    not reached
    480.3174 USD
    +12.60% from current
  • Resistance
    Fib +27.2% extension
    not reached
    455.2254 USD
    +6.72% from current
  • Current
    426.555 USD
  • Support
    Fib 23.6% retracementNearest
    tested 7×
    418.3853 USD
    -1.92% from current
  • Support
    Fib 38.2% retracement
    tested 11×
    407.7974 USD
    -4.40% from current
  • Support
    Fib 50% midpoint
    tested 22×
    399.24 USD
    -6.40% from current
  • Support
    Fib 61.8% retracement
    tested 9×
    390.6826 USD
    -8.41% from current
  • Support
    Fib 78.6% retracement
    tested 8×
    378.4993 USD
    -11.27% from current
  • Support
    Fib −27.2% extension
    not reached
    343.2546 USD
    -19.53% from current
  • Support
    Fib −61.8% extension
    not reached
    318.1627 USD
    -25.41% from current
  • Support
    Fib −100% extension
    not reached
    290.46 USD
    -31.91% from current
How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high
$436.24
52w low
$274.84
52w change
20.95%
Day high
$435.50
Day low
$425.00
P/E (TTM)
18.96
Forward P/E
14.53
PEG
1.4
Price / Book
2.08
Beta (5Y)
0.71
Enterprise value
86.97B
EV / Revenue
0.43
EV / EBITDA
10.45
EPS (TTM)
$22.69
Forward EPS
$29.60
Dividend yield
1.60%
Dividend rate
$6.88
Payout ratio
30.37%
Revenue (TTM)
201.11B
EBITDA
8.32B
Free cash flow
4.31B
Total cash
37.51B
Total debt
31.04B
Debt / Equity
68.95
Current ratio
1.52
Quick ratio
1.37
Profit margin
2.47%
Gross margin
25.99%
Return on assets
3.83%
Return on equity
11.13%
Shares outstanding
216.87M
Float
216.37M
Sector: HealthcareIndustry: Healthcare PlansHQ: United StatesEmployees: 96.13Kwww.elevancehealth.com

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Analyst & Risk

Consensus
Buy
Mean rating1.82 / 5
Analysts21
Next earnings2026-10-21
Strong buy 2Buy 12Hold 8
Analyst price target
$451.71
Mean target · 21 analysts
+5.9%
upside
Low $393.00Now $426.55High $492.00
Beta (vs S&P 500)
0.71
less volatile
52-week change
20.95%
Short % of float
2.51%
Short ratio (days)
3.9
Debt / Equity
68.95
very high leverage
Current ratio
1.52
Quick ratio
1.37
ROE
11.13%
ROA
3.83%
PEG ratio
1.4
fair
EV / Revenue
0.43
EV / EBITDA
10.45
Revenue growth
1.40%
Earnings growth
-13.10%
EBITDA
8.32B
Free cash flow
4.31B
Total cash
37.51B
Total debt
31.04B
Insider holdings
0.19%
Institutional
94.03%

Recent rating changes

  • 2026-10-12GuggenheimBuy → Buymain
  • 2026-10-07BarclaysOverweight → Overweightmain
  • 2026-07-17BernsteinOutperform → Outperformmain
  • 2026-07-17Leerink PartnersMarket Perform → Market Performmain
  • 2026-07-16RBC CapitalSector Perform → Sector Performmain
  • 2026-07-16Wells FargoOverweight → Overweightmain
  • 2026-07-16GuggenheimBuy → Buymain
  • 2026-07-16BarclaysOverweight → Overweightmain

Recent news

Related

Other assets in this category.

Learn the terms

Live discussion

Sign in to join the discussion.

  • No comments yet. Be the first.